{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:50:36Z","timestamp":1787323836082,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821520"],"award-info":[{"award-number":["821520"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004718","name":"Universit\u00e9 de Toulouse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004718","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40264-026-01672-8","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:01:02Z","timestamp":1780423262000},"page":"1085-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gabapentin and Pregabalin Use in First Trimester of Pregnancy and Risk of Specific Congenital Anomalies: An IMI ConcePTION European Case-Malformed Control Study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-100X","authenticated-orcid":false,"given":"Anna-Belle","family":"Beau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika Cifuentes","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Benevent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beslay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Barrachina-Bonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorieke E. H.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Cavero-Carbonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Coi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Dolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Garne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hoareau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elly Den","family":"Hond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Latos-Bielenska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lelong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O\u2019Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Moisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Neville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Sichitiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Loane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Damase-Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"1672_CR1","doi-asserted-by":"publisher","unstructured":"Beau A-B, Damase-Michel C, Mo J, Moisset X. Final study protocols for demonstration projects submitted to EU PAS register (D1.3) [Internet]. Zenodo; 2022. https:\/\/doi.org\/10.5281\/zenodo.7476130","DOI":"10.5281\/zenodo.7476130"},{"key":"1672_CR2","unstructured":"Brunton LL, Knollmann BC. Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, 14th Edition [Internet]. New York, NY: McGraw-Hill Education; 2023 [cited 2024 Dec 6]. accessmedicine.mhmedical.com\/content.aspx?aid=1198876907. Accessed 6 Dec 2024"},{"key":"1672_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.reprotox.2016.11.002","volume":"67","author":"A Furugen","year":"2017","unstructured":"Furugen A, Ishiguro Y, Kobayashi M, Narumi K, Nishimura A, Hirano T, et al. Involvement of l-type amino acid transporter 1 in the transport of gabapentin into human placental choriocarcinoma cells. Reprod Toxicol. 2017;67:48\u201355. https:\/\/doi.org\/10.1016\/j.reprotox.2016.11.002.","journal-title":"Reprod Toxicol"},{"key":"1672_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1111\/j.1528-1167.2005.00251.x","volume":"46","author":"I Ohman","year":"2005","unstructured":"Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia. 2005;46:1621\u20134. https:\/\/doi.org\/10.1111\/j.1528-1167.2005.00251.x.","journal-title":"Epilepsia"},{"key":"1672_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00232-001-0072-7","volume":"184","author":"HC Gong","year":"2001","unstructured":"Gong HC, Hang J, Kohler W, Li L, Su T-Z. Tissue-specific expression and gabapentin-binding properties of calcium channel \u03b12\u03b4 subunit subtypes. J Membr Biol. 2001;184:35\u201343. https:\/\/doi.org\/10.1007\/s00232-001-0072-7.","journal-title":"J Membr Biol"},{"key":"1672_CR6","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/pds.3847","volume":"24","author":"R Charlton","year":"2015","unstructured":"Charlton R, Garne E, Wang H, Klungs\u00f8yr K, Jordan S, Neville A, et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf. 2015;24:1144\u201354. https:\/\/doi.org\/10.1002\/pds.3847.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1672_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/pds.5035","volume":"29","author":"JM Cohen","year":"2020","unstructured":"Cohen JM, Cesta CE, Furu K, Einarsd\u00f3ttir K, Gissler M, Havard A, et al. Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: A study in the five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf. 2020;29:913\u201322. https:\/\/doi.org\/10.1002\/pds.5035.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1672_CR8","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/pds.4897","volume":"28","author":"C Hurault\u2010Delarue","year":"2019","unstructured":"Hurault\u2010Delarue C, Morris JK, Charlton R, Gini R, Loane M, Pierini A, et al. Prescription of antiepileptic medicines including valproate in pregnant women: a study in three European countries. Pharmacoepidemiol Drug Saf. 2019;28:1510\u20138. https:\/\/doi.org\/10.1002\/pds.4897.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1672_CR9","doi-asserted-by":"publisher","unstructured":"Beau A-B, Paoletti O, B\u00e9n\u00e9vent J, Beslay M, Barrachina-Bonet L, Cavero-Carbonell C, et al. Reason for Gabapentinoids Prescribing in Pregnancy: Results From Five European countries. A Contribution From the IMI ConcePTION Project. ABSTRACTS of the 2024 ISPE Annual Meeting, Berlin, Germany, 24\u201328 August 2024. Pharmacoepidemiology and Drug Safety. John Wiley & Sons, Ltd; 2024;33:e5891. https:\/\/doi.org\/10.1002\/pds.5891","DOI":"10.1002\/pds.5891"},{"key":"1672_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40264-023-01307-2","volume":"46","author":"E Dudukina","year":"2023","unstructured":"Dudukina E, Sz\u00e9pligeti SK, Karlsson P, Asomaning K, Daltveit AK, Hakkarainen K, et al. Prenatal exposure to pregabalin, birth outcomes and neurodevelopment \u2013 a population-based cohort study in four Nordic countries. Drug Saf. 2023;46:661\u201375. https:\/\/doi.org\/10.1007\/s40264-023-01307-2.","journal-title":"Drug Saf"},{"key":"1672_CR11","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1212\/WNL.0000000000007696","volume":"93","author":"P-O Bloti\u00e8re","year":"2019","unstructured":"Bloti\u00e8re P-O, Raguideau F, Weill A, Elefant E, Perthus I, Goulet V, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019;93:e167\u201380. https:\/\/doi.org\/10.1212\/WNL.0000000000007696.","journal-title":"Neurology"},{"key":"1672_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74409-x","volume":"10","author":"J Coste","year":"2020","unstructured":"Coste J, Bloti\u00e8re P-O, Miranda S, Mikaeloff Y, Peyre H, Ramus F, et al. Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep. 2020;10:17362. https:\/\/doi.org\/10.1038\/s41598-020-74409-x.","journal-title":"Sci Rep"},{"key":"1672_CR13","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1212\/WNL.0000000000003959","volume":"88","author":"E Patorno","year":"2017","unstructured":"Patorno E, Bateman BT, Huybrechts KF, MacDonald SC, Cohen JM, Desai RJ, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology. 2017;88:2020\u20135. https:\/\/doi.org\/10.1212\/WNL.0000000000003959.","journal-title":"Neurology"},{"key":"1672_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/jnnp-2023-333149","volume":"95","author":"H Forbes","year":"2024","unstructured":"Forbes H, Madley-Dowd P, Ahlqvist V, Campbell J, Davies NM, Liebling R, et al. First-trimester use of antiseizure medications and the risk of miscarriage: a population-based cohort study. J Neurol Neurosurg Psychiatry. 2024;95:693\u2013703. https:\/\/doi.org\/10.1136\/jnnp-2023-333149.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1672_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003322","volume":"17","author":"E Patorno","year":"2020","unstructured":"Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Med. 2020;17:e1003322. https:\/\/doi.org\/10.1371\/journal.pmed.1003322.","journal-title":"PLoS Med"},{"key":"1672_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ppe.13086","volume":"38","author":"B Desrochers","year":"2024","unstructured":"Desrochers B, Lavu A, Valencia E, Vaccaro C, Peymani P, Eltonsy S. Risks of congenital malformations and neonatal intensive care unit admissions with gabapentin use in pregnancy: A cohort study and scoping review with meta-analysis. Paediatr Perinat Epidemiol. 2024;38:486\u201394. https:\/\/doi.org\/10.1111\/ppe.13086.","journal-title":"Paediatr Perinat Epidemiol"},{"key":"1672_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100849","volume":"38","author":"J Christensen","year":"2024","unstructured":"Christensen J, Zoega H, Leinonen MK, Gilhus NE, Gissler M, Igland J, et al. Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. The Lancet Regional Health - Europe. 2024;38:100849. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100849.","journal-title":"The Lancet Regional Health - Europe"},{"key":"1672_CR18","unstructured":"EMA Gabapentin [Internet]. [cited 2024 Dec 6]. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/neurontin-article-30-referral-annex-i-ii-iii_en.pdf. Accessed 6 Dec 2024"},{"key":"1672_CR19","unstructured":"EMA Pregabalin [Internet]. [cited 2024 Dec 6]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pregabalin-sandoz-epar-product-information_en.pdf. Accessed 6 Dec 2024"},{"key":"1672_CR20","doi-asserted-by":"publisher","unstructured":"Beau A-B, Mo J, Moisset X, B\u00e9n\u00e9vent J, Damase-Michel C. Systematic review of gabapentinoid use during pregnancy and its impact on pregnancy and childhood outcomes: A ConcePTION study. Therapie. France; 2024;S0040-5957(24)00165-3. https:\/\/doi.org\/10.1016\/j.therap.2024.10.049","DOI":"10.1016\/j.therap.2024.10.049"},{"key":"1672_CR21","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/bdra.20780","volume":"91","author":"PA Boyd","year":"2011","unstructured":"Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, Dolk H. Paper 1: The EUROCAT network\u2014organization and processes\u2020. Birth Defects Res A Clin Mol Teratol. 2011;91:S2-15. https:\/\/doi.org\/10.1002\/bdra.20780.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"1672_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00228-009-0647-2","volume":"65","author":"I Lacroix","year":"2009","unstructured":"Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009;65:839\u201346. https:\/\/doi.org\/10.1007\/s00228-009-0647-2.","journal-title":"Eur J Clin Pharmacol"},{"key":"1672_CR23","doi-asserted-by":"publisher","unstructured":"Dolk H, Damase-Michel C, Morris J, Neville A, E G, Jordan S, et al. The EUROmediCAT network and databases: a resource for pharmacovigilance in pregnancy Short running title: The EUROmediCAT network and databases. Authorea; 2025. https:\/\/doi.org\/10.22541\/au.175394925.50330509\/v1","DOI":"10.22541\/au.175394925.50330509\/v1"},{"key":"1672_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00228-025-03814-w","volume":"81","author":"L Saint-Lary","year":"2025","unstructured":"Saint-Lary L, Beau A-B, Sommet A, Leroy V, Loane M, Cavero-Carbonell C, et al. Antiretroviral drug exposure in pregnancy and risk of congenital anomalies: a European case\/non-case malformed study. Eur J Clin Pharmacol. 2025;81:697\u2013709. https:\/\/doi.org\/10.1007\/s00228-025-03814-w.","journal-title":"Eur J Clin Pharmacol"},{"key":"1672_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2477","volume":"361","author":"JE Given","year":"2018","unstructured":"Given JE, Loane M, Garne E, Addor M-C, Bakker M, Bertaut-Nativel B, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ. 2018;361:k2477. https:\/\/doi.org\/10.1136\/bmj.k2477.","journal-title":"BMJ"},{"key":"1672_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.2435","volume":"117","author":"E-A Cifuentes","year":"2025","unstructured":"Cifuentes E-A, Beau A, Caillet A, Fr\u00e9mont F, Neville AJ, Ballardini E, et al. Risk of congenital ocular anomaly after prenatal exposure to medications: a EUROmediCAT study. Birth Defects Research. 2025;117:e2435. https:\/\/doi.org\/10.1002\/bdr2.2435.","journal-title":"Birth Defects Research"},{"key":"1672_CR27","unstructured":"EUROCAT. EUROCAT Guide 1.4: Instruction for the registration of congenital anomalies. EUROCAT Central Registry, University of Ulster [Internet]. 2013 [cited 2020 Dec 8]. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/JRC-EUROCAT-Full-Guide-1.4-version-15-Nov-2019.pdf. Accessed 8 Dec 2020"},{"key":"1672_CR28","unstructured":"Prakash, Prabhu LV, Rai R, Pai MM, Yadav SK, Madhyastha S, et al. Teratogenic effects of the anticonvulsant gabapentin in mice. Singapore Med J. India; 2008;49:47\u201353."},{"key":"1672_CR29","unstructured":"European Medicines Agency. Summary of the European public assessment report: Neurontin gabapentin. [Internet]. European Medicines Agency. 2006 [cited 2023 Feb 14]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/neurontin. Accessed 14 Feb 2023"},{"key":"1672_CR30","first-page":"1065","volume":"16","author":"L Etemad","year":"2013","unstructured":"Etemad L, Mohammad A, Mohammadpour AH, Vahdati Mashhadi N, Moallem SA. Teratogenic effects of pregabalin in mice. Iran J Basic Med Sci Iran. 2013;16:1065\u201370.","journal-title":"Iran J Basic Med Sci. Iran"},{"key":"1672_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s40264-015-0321-9","volume":"38","author":"L de Jonge","year":"2015","unstructured":"de Jonge L, Garne E, Gini R, Jordan SE, Klungsoyr K, Loane M, et al. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study. Drug Saf. 2015;38:1083\u201393. https:\/\/doi.org\/10.1007\/s40264-015-0321-9.","journal-title":"Drug Saf"},{"key":"1672_CR32","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s10654-015-0099-1","volume":"30","author":"H Dolk","year":"2015","unstructured":"Dolk H, Wemakor A. Response to: Case-control studies require appropriate population controls: an example of error in the SSRI birth defect literature. Eur J Epidemiol. 2015;30:1219\u201321. https:\/\/doi.org\/10.1007\/s10654-015-0099-1.","journal-title":"Eur J Epidemiol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01672-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01672-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01672-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:14:26Z","timestamp":1787321666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01672-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1672"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01672-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"XM has received financial support from Allergan-Abbvie, Amgen-Horizon, Aptyspharma, Biogen, BMS, Gr\u00fcnenthal, Lilly, Lundbeck, Teva, Merck-Serono, Novartis, Orion, Pfizer, Roche, Sanofi-Genzyme and Sun Pharma and non-financial support from Dr Reddy\u2019s and SOS Oxyg\u00e8ne not related to the submitted work. All other co-authors have no competing interests to disclose.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the EUROmediCAT database was provided by the Ulster University Nursing Research Governance Filter Committee. The EFEMERIS cohort was approved by the French Data Protection Agency on 7 April, 2005 (authorization number 05-1140). All contributing registries have their own ethics approval arrangements appropriate to their national and local ethics guidelines, and gave approval for their data to be used in this study. This study was performed on anonymized patient data.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data in EUROmediCAT are anonymized; therefore, patient informed consent for this particular study was not required. The women included in EFEMERIS database were informed of their inclusion and of the potential use of their anonymized data for research purposes. They can oppose the use of their data at any time.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific consent for this publication was obtained from women.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EUROmediCAT encourages the use of its data and networks for pharmacovigilance and medication safety research. Individual data are only available to consortium members; however, EUROmediCAT can be commissioned to do a study, or engage in a collaborative study. Requests can be made at\n                      \n                      .","order":5,"name":"Ethics","label":"Availability of data and material:","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was registered in the EUPAS Registry (EUPAS43385) and is available from the zenodo repository:\n                      \n                      [\n                      \n                      ]","order":6,"name":"Ethics","label":"Code availability:","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was primarily conceived and designed by ABB and CDM. ML provided access to the EUROmediCAT Central Database. M-C A, JB, AC, EG, MG, JH, EDH, A L-B, NL, and MM reviewed and confirmed exposure and congenital anomalies classification of their exposed cases. EG and ML reviewed the congenital anomalies classification and provided input in the case series description. The data curation and statistical analyses were performed by ECC. ABB and ECC drafted the manuscript and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions:","group":{"name":"EthicsHeading","label":"Declarations"}}]}}